Search CELG-RI
BRISTOL MYERS SQUIBB CO
NYSE, NYSE · CIK 14272
Last close0.13
Daily change+0.00 (3.44%)
10 Years gain+7.67%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CELG-RI · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
20.3Momentum
n/aAcceleration
n/aConfidence
73.0Annual Revenue19
Quarterly Revenue83
Annual CFO19
Balance SheetAvailable
RankingLimited
Score Breakdown
Growth2.0 / 25
Quality9.4 / 25
Capital Efficiency0.0 / 20
Balance Sheet7.9 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.6583 percentage points.
Key Metrics
Revenue Growth TTM3.8%OK
Revenue CAGR 3Y1.45%OK
Gross Margin71.5%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.39%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $48.19B | $34.26B | n/a | $14.16B | $12.85B | 71.08% | n/a | 26.65% | n/a | 2.04B |
| 2025 FY Dec 31, 2024 | $48.30B | $34.33B | n/a | $15.19B | $13.94B | 71.08% | n/a | 28.87% | n/a | 2.03B |
| 2025 FY Dec 31, 2023 | $45.01B | $34.31B | n/a | $13.86B | $12.65B | 76.24% | n/a | 28.11% | n/a | 2.08B |
| 2024 FY Dec 31, 2022 | $46.16B | $36.02B | n/a | $13.07B | $11.95B | 78.04% | n/a | 25.88% | n/a | 2.15B |
| 2023 FY Dec 31, 2021 | $46.39B | $36.45B | n/a | $16.21B | $15.23B | 78.57% | n/a | 32.84% | n/a | 2.25B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $48.95B | sum latest 4 fiscal quarters Revenue | OK | 0000014272-26-000020, 0000014272-25-000149 |
| Revenue Growth TTM | 3.8% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000014272-26-000020, 0000014272-25-000149 |
| Revenue CAGR 3Y | 1.45% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000014272-26-000004 |
| Revenue CAGR 5Y | 2.54% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000014272-26-000004 |
| Gross Profit CAGR 3Y | -1.66% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000014272-26-000004 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 71.5% | Gross Profit / Revenue | OK | 0000014272-26-000020, 0000014272-25-000149 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000014272-26-000020 |
| Current Ratio | 1.53x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.26x | (Cash + Short-term Investments) / Total Debt | OK | 0000014272-26-000020 |
| Revenue per Diluted Share | $23.90 | Revenue / Diluted Shares | OK | 0000014272-26-000020, 0000014272-25-000149 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | 71.52% | Cash dividends paid / Net income | OK | 0000014272-26-000004 |